Biotechnology seeks solutions for Parkinson's, the second most common neurodegenerative di... 11/04/2024 Approximately 10,000 new cases of Parkinson's are detected each year in Spain, with a total figure exceeding 150,000... AseBio
ORYZON announces U.S. FDA clearance of CTEP-CRADA Phase I/II clinical trial sponsored by N... 08/04/2024 Healthcare Access to innovation In combination with either atezolizumab or durvalumab. Partners - Oryzon Genomics
#AseBioID24 | "AseBio Investor Day is a unique meeting point for companies and investors s... 08/04/2024 Healthcare Access to innovation Financing With the aim of analyzing the Spanish biotechnological ecosystem and delving into the challenges and opportunities it... AseBio - Euronext
Revolution in Pain Management straight from Spain: Introducing the Spinally Medical 08/04/2024 Healthcare Access to innovation Spinally Medical introduces FuturaLead™, a subarachnoid device for spinal cord stimulation aimed at patients suffering... Partners
The Spanish AI Healthcare Landscape 04/04/2024 Healthcare Access to innovation Rare diseases Personalized medicine While not yet a global player, Artificial Intelligence (AI) is increasingly being integrated into the healthcare... Partners - OWKIN
ORYZON receives the INNOVATIVE SME seal from the Spanish Ministry of Science and Innovati... 04/04/2024 Healthcare Access to innovation La compañía biofarmacéutica ya ha sido inscrita en el Registro de Público de PYMES INNOVADORAS. Partners - Oryzon Genomics
Celtarys Research, USC-biofarma and ZeClinics seek new therapeutic targets for Parkinson's... 01/04/2024 Healthcare Access to innovation Drug discovery Innovative drugs Advanced therapies This project, coordinated by Asebio, brings together ZeClinics' target validation and in vivo drug screening... AseBio
Almirall signs licensing agreement with Eloxx Pharmaceuticals and enters the field of rare... 25/03/2024 Healthcare Access to innovation Rare diseases Personalized medicine Advanced therapies The Spanish pharmaceutical company has obtained global rights to develop and commercialize the drug ZKN-013. Partners - Almirall
The European Virtual Biotechnology Forum: Next Generation Sequencing Advancements and Ris... Online Del 03/04/2024 15:00 to 03/04/2024 17:10 Healthcare Access to innovation International Digitalization The European Biotechnology Forum: Next Generation Sequencing Advancements and Risks: Next-Generation-Sequencing (NGS)...
Spanish biotechnology leads the global fight against tuberculosis 24/03/2024 Healthcare Access to innovation Innovative drugs On the occasion of World Tuberculosis Day, we delve into the advances achieved by the candidate vaccine against... AseBio - Zendal
